Results 131 to 140 of about 8,627 (176)

Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design. [PDF]

Res Pract Thromb Haemost, 2018
Luciani M, Albisetti M, Biss B, Bomgaars L, Brueckmann M, Chalmers E, Gropper S, Halton JML, Harper R, Huang F, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Brandão LR.   +14 more
europepmc   +1 more source

Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography. [PDF]

Medicine (Baltimore), 2018
Xing XF, Liu NN, Han YL, Zhou WW, Liang M, Wang ZL.   +5 more
europepmc   +1 more source

Modulatory Effects of Dabigatran on PAR-1 Activity and Viability in Adipose-Derived Mesenchymal Stem Cells. [PDF]

Int J Mol Sci
Kubat E, Gürpınar ÖA, Özdem T.
europepmc   +1 more source

Kidney injury associated with direct oral anticoagulants: a comparative study of direct thrombin inhibitors and factor Xa inhibitors based on literature and database analysis. [PDF]

Ren Fail
Chen S, Shi C, Li X, Wang X, Guo R, Wu T.   +5 more
europepmc   +1 more source

Research Advances in Timing of Anticoagulant Therapy Following Cardioembolic Stroke. [PDF]

Clin Med Insights Cardiol
Rousidanmu M, Yang N, Yang P, Yan N.
europepmc   +1 more source

Brandão LR, Albisetti M, Halton J, et al; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491-504.

Blood, 2020
europepmc   +1 more source

Dabigatran-induced acute hepatitis in a patient with atrial fibrillation: a rare case report. [PDF]

Eur Heart J Case Rep
Hsu CW, Chang HR, Wu SC.
europepmc   +1 more source